Document is current
Any future updates will be listed below
-
Authors
Hiraiwa, Hiroaki https://orcid.org/0000-0002-1606-7037
Yura, Yoshimitsu https://orcid.org/0000-0003-2618-8569
Okumura, Takahiro https://orcid.org/0000-0001-5076-2052
Murohara, Toyoaki https://orcid.org/0000-0003-2723-6243
-
Funding
Funding for this research was provided by:
Nagoya University
- License Information
-
More Information
Article History
Accepted: 3 July 2024
First Online: 10 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Hiroaki Hiraiwa declares the following: research grants from Konica Minolta, Inc., Konica Minolta Science and Technology Foundation, and Kowa Life Science Foundation. Yoshimitsu Yura declares the following: research grants from Japan Foundation for Applied Enzymology, Kowa Life Science Foundation, MSD Life Science Foundation, Mitsubishi Foundation, Suzuken Memorial Foundation, the Hori Science and Arts Foundation, Mochida Foundation, Takeda Science Foundation, Sakakibara Heart Foundation, and Japan Heart Foundation. Takahiro Okumura declares the following: research grants from Ono Pharmaceutical Co. Ltd., Amgen Astellas BioPharma K.K., Pfizer Japan Inc., Alnylam Pharmaceuticals, Inc., and Alexion Pharmaceuticals, Inc. Takahiro Okumura received lecture fees from Ono Pharmaceutical Co. Ltd., Otsuka Pharma Ltd., Novartis Pharma K.K., and AstraZeneca K.K. Toyoaki Murohara declares the following: an unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma Inc., Daiichi-Sankyo Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Kowa Co. Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis K.K., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. All authors declare that they have no relationships with industry relevant to the contents of this paper.
